Prof. Dr. med. Hans-Joachim Schmoll

Transcription

1 Prof. Dr. med. Hans-Joachim Schmoll PubMed N Publications; 445 Cumulative Impact Factor: 1697 Web of Science: h (Hirsch-) Factor: 71 Journalbeitrag 1. Schwoon DR, Schmoll HJ: (1979) Motivation to participate in cancer screening programmes. SOC SCI MED, 13: Summe Bewertung = 0 1. Schmoll HJ, Niederle N, Achterrath W: (1981) [Etoposide VP )--a podophyllotoxinderivative with high antitumor activity (author's transl)]. KLIN WOCHENSCHR, 59: Summe Bewertung = 0 1. Weiss J, von Roemeling R, Peters HD, Schmoll HJ, Diehl V: (1983) [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone]. DEUT MED WOCHENSCHR, 108: Summe Bewertung = 0 1. Gabius HJ, Engelhardt R, Casper J, Reile D, Schumacher S, Schmoll HJ, Graupner G, Cramer F: (1985) Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectin. TUMOR BIOL, 6:

2 1985 Summe Bewertung = 0 1. Gabius HJ, Engelhardt R, Casper J, Schmoll HJ, Nagel GA, Cramer F: (1986) Comparison of endogenous lectins in human embryonic carcinoma and yolk sac carcinoma. TUMOR BIOL, 6: Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Gluck S, Gorg K, Gramatzki M, et A: (1986) Current results of a multicenter trial in multiple myeloma. ONKOLOGIE, 9: Summe Bewertung = 0 Summe IF = 0 1. Berdel WE, Berger MR, Falk H, Harstrick A, Danhauser S, Schick HD, Schmoll HJ, Schmahl D, Vogler WR, Rastetter J: (1987) Lack of therapeutic activity of the lipoidal amine CP-46,665 in rodent tumors and human non-seminomatous germ cell tumors growing in nude mice. CANCER LETT, 38: Casper J, Schmoll HJ, Schnaidt U, Fonatsch C: (1987) Cell lines of human germinal cancer. INT J ANDROL, 10: Creutzig A, Polking W, Schmoll HJ, Fabel H, Alexander K: (1987) [Raynaud syndrome and changes in lung function as sequelae of cytostatic therapy of testicular tumors]. MED KLIN-INTENSIVMED, 82: Gabius HJ, Bokemeyer C, Hellmann T, Schmoll HJ: (1987) Targeting of neoglycoprotein-drug conjugates to cultured human embryonal carcinoma cells. J CANCER RES CLIN, 113: Harstrick A, Casper J, Schmoll HJ: (1987) Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts. INT J ANDROL, 10: Schmoll HJ, Schubert I, Arnold H, Dolken G, Hecht T, Bergmann L, Illiger J, Fink U, Preiss J, Pfreundschuh M, et A: (1987) Disseminated testicular cancer with bulky disease: results of a phase-ii study with cisplatin ultra high dose/vp-16/bleomycin. INT J ANDROL, 10:

3 1987 Summe Bewertung = 0 1. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, Schmoll HJ, Dietrich H, Hain E: (1988) Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from KLIN WOCHENSCHR, 66: Peest D, Schmoll HJ, Schedel I, Gluck S, Schumacher K, Deicher H: (1988) VBAMDex chemotherapy in advanced multiple myeloma. EUR J HAEMATOL, 40: Verbeek W, Bokemeyer C, Falk H, Schmoll HJ: (1988) Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell lines. J CANCER RES CLIN, 114: Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L: (1988) Etoposide and split-dose cisplatin in small-cell lung cancer. AM J CLIN ONCOL-CANC, 11: Wilke H, Schmoll HJ, Preusser P, Fink U, Stahl M, Schober C, Link H, Freund M, Hanauske A, Meyer HJ, et A: (1988) Folinic acid (CF)/5-fluorouracil (FUra) combinations in advanced gastrointestinal carcinomas. ADV EXP MED BIOL, 244: Wilke H, Schmoll HJ, Schober C, Stahl M, Preusser P, Freund M, Poliwoda H: (1988) Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. BIOMED PHARMACOTHER, 42: Summe Bewertung = 0 1. Arnemann J, Gradl G, Casper J, Schmoll HJ, Schmidtke J, Fonatsch C: (1989) Characterization of rearranged Y chromosomes in human testicular tumor cell lines. CANCER GENET CYTOGEN, 37: Bokemeyer B, Grote R, Schmoll E, Freise J, Schmoll HJ, Galanski M, Schuler A, Schmidt FW: (1989) [Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin and cisplatin]. DEUT MED WOCHENSCHR, 114:

4 3. Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ: (1989) Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro. CANCER-AM CANCER SOC, 63: Schmoll HJ: (1989) The role of ifosfamide in testicular cancer. SEMIN ONCOL, 16(1 Suppl 3): Winkler K, Torggler S, Beron G, Bode U, Gerein V, Jurgens H, Kusnierz-Glaz C, Kotz R, Salzer-Kuntschik M, Schmoll HJ, et A: (1989) [Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative osteosarcoma studies COSS-80 and COSS-82]. ONKOLOGIE, 12: Summe Bewertung = 0 Summe IF = 0 1. Harstrick A, Casper J, Kohne-Wompner H, Wilke H, Schmoll HJ, Poliwoda H: (1990) Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines. INVEST NEW DRUG, 8: S Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H: (1990) Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents. EUR J CANCER, 26: Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wompner CK, Bokemeyer C, Dolken G, Burk K, Poliwoda H: (1990) High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. ANN ONCOL, 1: Jackle-Meyer I, Gwinner W, Baum M, Soose M, Petzoldt R, Schmoll HJ, Stolte H: (1990) Significance of Tamm-Horsfall protein excretion in diabetes mellitus and cisplatin nephrotoxicity. CONTRIB NEPHROL, 83: Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, Meyer HJ, Meyer J, Blum M, Schmoll HJ: (1990) Phase II study of carboplatin in untreated inoperable advanced stomach cancer. EUR J CANCER, 26: Schmoll HJ: (1990) Progress in treatment of testicular cancer. J CANCER RES CLIN, 116:

5 7. Schmoll HJ, Harstrick A, Kohne-Wompner CH, Schober C, Wilke H, Poliwoda H: (1990) Modulation of cytotoxic drug activity by dipyridamole. CANCER TREAT REV, 17: Tesch H, Furbass R, Casper J, Lyons J, Bartram CR, Schmoll HJ, Bronson DL: (1990) Cellular oncogenes in human teratocarcinoma cell lines. INT J ANDROL, 13: Summe Bewertung = 0 Summe IF = 0 1. Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Rath U, Siegert W, et A: (1991) Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma. J CANCER RES CLIN, 117: S Harstrick A, Schmoll HJ, Kohne-Wompner CH, Bergmann L, Lammers U, Hohnloser J, Dolken G, Reichhardt P, Siegert W, Natt F, et A: (1991) Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. ANN ONCOL, 2: Harstrick A, Schmoll HJ, Wilke H, Kohne-Wompner CH, Stahl M, Schober C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, et A: (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J CLIN ONCOL, 9: Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ: (1991) Megestrol acetate in cancer cachexia. SEMIN ONCOL, 18(1 Suppl 2): Schmoll HJ: (1991) How should we treat disseminated seminoma? ANN ONCOL, 2: Schmoll HJ: (1991) Introduction: the clinical challenge. EUR J CANCER, 27: S Schuppert F, Scheumann GFW, Schöber C, Overbeck J, Schürmeyer T, Schmoll HJ, Dralle H, von zur Mühlen A: (1991) Therapie eines malignen sympathischen

6 Paraganglioms des Zuckerkandlschen Organs - ein Fallbericht. KLIN WOCHENSCHR, 69: Wilke H, Preusser P, Stahl M, Harstrick A, Meyer HJ, Achterrath W, Schmoll HJ, Seeber S: (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. CANCER CHEMOTH PHARM, 29: Summe Bewertung = 0 Summe IF = 0 1. Bokemeyer C, Freund M, Schmoll HJ, Rieder H, Fonatsch C: (1992) Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour. ANN ONCOL, 3: Bokemeyer C, Harstrick A, Schmoll HJ, Kohne-Wompner CH, Schoffski P, Poliwoda H: (1992) Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ANN ONCOL, 3: Bokemeyer C, Harstrick A, Schoffski P, Schmoll HJ, Poliwoda H: (1992) [Germ-cell tumors of the testis. The epidemiological and etiological aspects]. DEUT MED WOCHENSCHR, 117: Galanski M, Schmoll E, Reichelt S, Bohmer G, Prokop M, Schaefer C, Schuler A, Ringe B, Schmidt FW, Schmoll HJ: (1992) [Chemoembolization of hepatocellular carcinoma in cases of isolated liver involvement]. RADIOLOGE, 32: Harstrick A, Bokemeyer C, Preusser P, Kohne-Wompner CH, Meyer HJ, Stahl M, Knipp H, Schmoll HJ, Wilke H: (1992) Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. CANCER CHEMOTH PHARM, 29: Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM: (1992) Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. SEMIN ONCOL, 19(2 Suppl 3): Schmoll HJ, Bokemeyer C, Harstrick A, Illiger HJ, Metzner B, Ruther U, Osternamm A, Preiss J, Wilke H, Hohnloser J, et A: (1992) Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors. PATHOL BIOL, 39:

7 8. Schmoll HJ, Hiddemann W, Rustum Y, Kohne-Wompner CH: (1992) The emerging role for biomodulation of antineoplastic agents. SEMIN ONCOL, 19(2 Suppl 3): Schmoll HJ, Kohne-Wompner CH, Hiddemann W, Knipp H, Wilke H, Bodenstein H, Schoffski P, Bokemeyer C, Lohrmann HP, Preiss J, et A: (1992) Interferon alpha-2b, 5- fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial. SEMIN ONCOL, 19(2 Suppl 3): Schober C, Bokemeyer C, Stahl M, Wilke HJ, Schmoll HJ, Poliwoda H: (1992) The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. SEMIN ONCOL, 19(2 Suppl 3): Schober C, Kohne-Wompner CH, Schmoll HJ, Stahl M, Wilke HJ, Poliwoda H: (1992) A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. SEMIN ONCOL, 19(2 Suppl 3): Schober C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M, Bokemeyer C, Wilke H, Weiss J: (1992) Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. EUR J CANCER, 28: Stahl M, Wilke HJ, Seeber S, Schmoll HJ: (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. SEMIN ONCOL, 19(2 Suppl 4): Stahl M, Wilke H, Schmoll HJ, Schober C, Diedrich H, Casper J, Freund M, Poliwoda H: (1992) A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. ANN ONCOL, 3: Wilke H, Stahl M, Schmoll HJ, Preusser P, Fink U, Meyer HJ, Achterrath W, Knipp H, Kohne-Wompner CH, Harstrick A, et A: (1992) Biochemical modulation of 5- fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. SEMIN ONCOL, 19(2 Suppl 3): Summe Bewertung = 0 Summe IF = 0

8 1. Bokemeyer C, Kuczyk M, Schoffski P, Schmoll HJ: (1993) Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. J UROLOGY, 150(5 Pt 1): Bokemeyer C, Luer M, Schmoll HJ, Freund M, Poliwoda H: (1993) Secondary cancer following Hodgkin's disease. ANN ONCOL, 4: Bokemeyer C, Schmoll HJ: (1993) Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). EUR UROL, 23: 223-9; discussion Bokemeyer C, Schmoll HJ: (1993) Treatment strategies in metastatic testicular cancer. EUR UROL, 23: Bokemeyer C, Schmoll HJ: (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J CLIN ONCOL, 11: Bokemeyer C, Schmoll HJ, Harstrick A: (1993) Side-effects of GM-CSF treatment in advanced testicular cancer. EUR J CANCER, 29: Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzner B, Rath U, Hohnloser J, Clemm C, Berdel W, Siegert W, et A: (1993) A phase I/II study of a stepwise doseescalated regimen of cisplatin, etoposide and ifosfamide plus granulocytemacrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. EUR J CANCER, 29: Bokemeyer C, Schmoll HJ, Metzner B, Beyer J, Illiger HJ, Kneba M, Ostermann H, Kynast B, Rath U, Poliwoda H: (1993) Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer. ANN HEMATOL, 67: Bokemeyer C, Schmoll HJ, Schoffski P, Harstrick A, Bading M, Poliwoda H: (1993) Bilateral testicular tumours: prevalence and clinical implications. EUR J CANCER, 29: Erlichman C, Fine S, Kerr I, Hoffman W, Gorg C, Schmoll HJ, Preusser P, Senn HJ, Gustavsson B: (1993) Experience with 5FU + L-leucovorin. ADV EXP MED BIOL, 339: 77-9; discussion

9 11. Grigor KM, Schmoll HJ: (1993) How should we identify high risk testicular tumour patients? Round table discussion. EUR UROL, 23: Grigor KM, Schmoll HJ: (1993) Should high dose chemotherapy with, or without, autologous bone marrow transplant be included in the primary treatment of testicular cancer? Round table discussion. EUR UROL, 23: Grundner-Culemann E, Bokemeyer C, Neubauer V, Shalitin C, Schmoll HJ, Poliwoda H, Benter T: (1993) Analysis of a non-ras 21-kDa protein in patients with metastatic testicular germ-cell tumors. J CANCER RES CLIN, 119: Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: (1993) Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and - resistant human testicular, ovarian, and gastric carcinoma cell lines. CANCER CHEMOTH PHARM, 33: Harstrick A, Bokemeyer C, Schmoll HJ, Kohne-Wompner CH, Knipp H, Schoffski P, Anagnou J, Wipperman B, Neumann S, Poliwoda H: (1993) A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. CANCER CHEMOTH PHARM, 31: S Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y: (1993) Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. EUR J CANCER, 29: Kohne-Wompner CH, Schmoll HJ: (1993) 5-Fluorouracil modulation in colorectal carcinoma experience of German investigators. ADV EXP MED BIOL, 339: Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: (1993) Determination of a fragment of the c-erbb-2 translational product p185 in serum of breast cancer patients. J CANCER RES CLIN, 119: Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schober C, Wilke H, Poliwoda H: (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. CANCER-AM CANCER SOC, 72: Schmoll HJ, Seeber S: (1993) [Current developments in chemotherapy of advanced testicular tumors]. UROLOGE, 32:

10 1993 Summe Bewertung = 0 Summe IF = 0 1. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1994) Treatment intensification in disseminated germ-cell tumors. WORLD J UROL, 12: , Bokemeyer C, Dunn T, Harstrick A, Lerch T, Poliwoda H, Schmoll HJ: (1994) Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents. INT J CANCER, 56: IF: 3, Bokemeyer C, Harstrick A, Ruther U, Metzner B, Illiger HJ, Clemm C, Siegert W, Link H, Ostermann H, Schmoll HJ: (1994) The role of granulocyte-macrophage colonystimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 21(6 Suppl 16): IF: 2, Bokemeyer C, Harstrick A, Schmoll HJ: (1994) The use of carboplatin in malignant germ cell tumours. EUR J CANCER, 30: , Bokemeyer C, Schmoll HJ, Ludwig E, Harstrick A, Dunn T, Casper J: (1994) The antitumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. BRIT J CANCER, 69: IF: 3, Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatinrefractory testicular cancer. J CANCER RES CLIN, 120: IF: 1, Bokemeyer C, Schmoll HJ, Poliwoda H: (1994) [Secondary leukemias after etoposide chemotherapy]. DEUT MED WOCHENSCHR, 119: , Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H: (1994) Long-term gonadal toxicity after therapy for Hodgkin's and non-hodgkin's lymphoma. ANN HEMATOL, 68: IF: 1, Derigs HG, Huber C, Schmoll HJ: (1994) [Stage-oriented therapy in nonseminomatous testicular tumors]. DEUT MED WOCHENSCHR, 119: , Hill BT, Shellard SA, Fichtinger-Schepman AM, Schmoll HJ, Harstrick A: (1994) Differential formation and enhanced removal of specific cisplatin-dna adducts in two cisplatin-selected resistant human testicular teratoma sublines. ANTI-CANCER DRUG,

11 5: IF: 1, Kohne-Wompner CH, Schoffski P, Schmoll HJ: (1994) Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation. ANN ONCOL, 5: IF: 1, Link H, Herrmann F, Welte K, Aulitzky WE, Ganser A, Kern WV, Meyer P, Schrappe M, Schmoll HJ, Werdan K, et A: (1994) [Rational therapy with G-CSF and GM-CSF]. MED KLIN-INTENSIVMED, 89: Schmoll HJ: (1994) Colorectal carcinoma: current problems and future perspectives. ANN ONCOL, 5: IF: 1, Schmoll HJ: (1994) [Adjuvant chemotherapy in rectal cancer]. CHIRURG, 65: , Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D: (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J CLIN ONCOL, 12: IF: 7, Summe Bewertung = 6,91752 Summe IF = 28, Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ: (1995) Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J CLIN ONCOL, 13: IF: 6, Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ: (1995) Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. EUR J CANCER, 31: IF: 2, Bokemeyer C, Kynast B, Harstrick A, Laage E, Schmoll E, von Wussow P, Schmoll HJ: (1995) No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. CANCER CHEMOTH PHARM, 35: IF: 1,598

12 4. Bokemeyer C, Ludwig E, Reile D, Harstrick A, Poliwoda H, Schmoll HJ: (1995) Antitumour activity and toxicity of continuous infusion versus bolus administration of bleomycin in two heterotransplanted human testicular cancer cell lines. ONCOL REP, 2: , Bokemeyer C, Schmoll HJ: (1995) Treatment of testicular cancer and the development of secondary malignancies. J CLIN ONCOL, 13: IF: 6, Bokemeyer C, Schmoll HJ: (1995) Sekundärneoplasien nach der Therapie maligner Keimzelltumoren des Hodens. STRAHLENTHER ONKOL, 6: Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W: (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. JNCI-J NATL CANCER I, 87: IF: 10, Köhne CH, Hiddemann W, Schüller J, Weiss J, Lorhmann HP, Schmitz-Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, Schmoll HJ: (1995) Failure of orally administered Dipyridamole to enhance the antineoplastic activity for Fluorouracil in combination with Leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J CLIN ONCOL, 13: IF: 6, Köhne CH, Schmoll HJ: (1995) Therapiestudien zur adjuvanten und palliativen Therapie. ONKOLOGE, 1: Köhne CH, Schmoll HJ, Wilke H, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Bade J, Strohmeyer G, Schöffski P, Schubert U, Hecker H: (1995) Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer: First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). ANN ONCOL, 6: IF: 2, Kuczyk MA, Bokemeyer C, Fichna B, Truss M, Schmoll HJ, Jonas U: (1995) [Differentiated teratoma as late recurrence of metastatic non-seminomatous testicular germ cell tumor. Case report and clinical problems]. UROLOGE, 34: , Kuczyk MA, Bokemeyer C, Schmoll HJ, Jonas U: (1995) The prognostic role of alterations of the p53 tumor suppressor gene in superficial and advanced stage bladder cancer. ONKOLOGIE, 18: ,462

13 13. Rhomberg W, Schmoll HJ, Schneider B: (1995) High frequency of metalworkers among patients with seminomatous tumors of the testis: a case-control study. AM J IND MED, 28: , Thiel I, Schmoll HJ, Bokemeyer C: (1995) Primary osteogenic sarcoma of the breast: Report of a case and a short review of the literature. ONKOLOGIE, 18: , Summe Bewertung = 9,29561 Summe IF = 39, Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwercman A, Hata JI, von Keitz A, Looijenga LHJ, Millan JL, Oosterhuis JW, Pera M, Sawada M, Schmoll HJ, Skakkebaek NE, van Putten W, Stern P: (1996) Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumors. INT J CANCER, 66: IF: 3, Berger C, Bokemeyer C, Schuppert F, Schmoll HJ: (1996) Endocrinological late effects after chemotherapy for testicular cancer. BRIT J CANCER, 73: IF: 3, Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1996) Hochdosischemotherapie bei Hodentumoren. ONKOLOGE, 2: Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W: (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J CLIN ONCOL, 14: IF: 7, Beyer J, Kramer A, Mandanas R, Linkesch W, Greinix A, Droz JP, Culine S, Diehl A, Bokemeyer C, Schmoll HJ, Einhorn LH, Nichols CR, Siegert W: (1996) Treatment outcome of high-dose chemotherapy as salvage treatment in male germ cell tumors: a multivariate analysis of prognostic factors. J CLIN ONCOL, 14: IF: 7, Bokemeyer C, Beyer J, Metzner B, Rüther U, Weißbach L, Köhrmann U, Verbeek W, Harstrick A, Schmoll HJ: (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory cancer. ANN ONCOL, 7: IF: 2, Bokemeyer C, Fels LM, Dunn TA, Voigt W, Gaedeke J, Schmoll HJ, Stolte H: (1996) Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide antitumor activity. BRIT J CANCER, 74:

14 IF: 3, Bokemeyer C, Köhrmann O, Tischler J, Weißbach L, Räth U, Haupt A, Schöffski P, Schmoll HJ: (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good risk metastatic non-seminomatous germ cell tumors. ANN ONCOL, 7: IF: 2, Bokemeyer C, Kuczyk MA, Dunn TA, Serth T, Hartmann K, Jonasson J, Jonas U, Schmoll HJ: (1996) Expression of stem cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumors. J CANCER RES CLIN, 122: IF: 1, Bokemeyer C, Kuczyk MA, Köhne CH, Einsele H, Kynast B, Schmoll HJ: (1996) Hematopoetic growths factors and treatment of testicular cancer: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 72: 1-9 IF: 1, Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ: (1996) Treatment of testicular cancer and hematopoietic growth factors: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 7: 1-9 IF: 1, Bokemeyer C, Kuczyk MA, Köhne H, Haupt A, Schmoll HJ: (1996) Das Risiko sekundärer Neoplasien nach Behandlung maligner Keimzelltumoren des Hodens. MED KLIN-INTENSIVMED, 91: Bokemeyer C, Kuczyk MA, Serth, Hartmann JT, Schmoll HJ, Jonas U, Kanz L: (1996) Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J CANCER RES CLIN, 122: IF: 1, Bokemyer C, Berger C, Kuczyk MA, Schmoll HJ: (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J CLIN ONCOL, 14: IF: 7, Borchard E, Engelhardt, Frommhold, Hartung, Hermanek, Herrmann, Hossfeld, Junginger, Kirchner, Kreuser, Meyer, Müller, Pichlmaier, Queißer, Schlag, Schmoll, Stock, Wilke: (1996) Konsens der CAO, AOI und ARO zur Diagnostik und Therapie des primären Magenlymphoms. ONKOLOGIE, 19: , Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J: (1996) Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. ANTI-CANCER DRUG, 7: 1-5 IF: 1,397

15 17. Erlichman C, Fine S, Kerr I, Hoffmann W, Görg C, Schmoll HJ, Preusser P, Thuerlimann B, Gustavsson B: (1996) A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. AM J CLIN ONCOL-CANC, 19: 26-31, Fels LM, Bokemeyer C, van Rhee J, Schmoll HJ, Stolte H: (1996) Evaluation of late nephrotoxicity in long-term survivors of Hodgkin's disease. ONCOLOGY-BASEL, 53: IF: 2, Hartmann JT, Thiel I, Schmoll HJ, Einsele H, Kanz L, Bokemeyer C: (1996) Malignant fibrous histiocytoma of bone - review of thirteen cases. ONCOL REP, 3: 1-5, Rambusch EG, Schuppert F, Müller-Kunert E, Stöcker W, Bokemeyer C, Schmoll HJ, von zur Mühlen A: (1996) Zytokintherapie und Endokrinium: Ist es sinnvoll, mehr als die Schilddrüse zu untersuchen? MED KLIN-INTENSIVMED, 91: Rüther U, Nunnensiek C, Sessler R, Stilz S, Ulshöfer T, Müller HAG, Bader H, Bokemeyer C, Schmoll HJ, Toomes H, Jipp P: (1996) Efficacy of antiestrogen treatment in a benign metastasizing leimyoma with paraneoplastic estradiol production. ONCOL REP, 3: , Schmoll HJ: (1996) Die Therapie von Keimzelltumoren: Modell für eine interdisziplinäre Behandlungsstrategie. MED KLIN-INTENSIVMED, 3: Schmoll HJ: (1996) Development of Treatment for Advanced Colorectal Cancer: Infusional 5-FU and the role of new agents. EUR J CANCER, 32: S18-22 IF: 2, Schmoll HJ, Bokemeyer C: (1996) Sequential intermediate high-dose chemotherapy in the primary treatment of poor risk testicular cancer. BONE MARROW TRANSPL, 18: IF: 2, Summe Bewertung = 11,64513 Summe IF = 55, Bamberg M, Schmoll HJ, Weißbach L, Beyer J, Bokemeyer C, Harstrick A, Höltl W, Souchon R, Vogler H: (1997) An interdiciplinary consensus conference on the diagnosis and therapy of testicular tumors. STRAHLENTHER ONKOL, 173: Berkovic D, Grundel O, Berkovic K, Wildfang I, Hess CF, Schmoll HJ: (1997) Synergistic cytotoxic effects of either phospholipid analogues and ionizing radiation in human

16 carcinoma cells. RADIOTHER ONCOL, 43: IF: 1, Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: (1997) A Phase I/ II Study of Sequential, Dose-Escalated, High-Dose Ifosfamide plus Doxorubicin with Peripheral Blood Stem Cell Support for the Treatment of Patients with Advanced Soft Tissue Sarcomas. CANCER-AM CANCER SOC, 6: IF: 3, Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ: (1997) Treatment of brain metastases in patients with testicular cancer. J CLIN ONCOL, 15: IF: 7, Dunn TA, Schmoll HJ, Grünewald V, Bokemeyer C, Casper J: (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. INVEST NEW DRUG, 15: , Dunn T, Schmoll HJ, Grünewald V, Casper J, Bokemeyer C: (1997) Pre-clinical activity of taxol in nonseminomatous germ cell tumor cell lines and nude mouse xenografts. INVEST NEW DRUG, 15: 91-98, Harstrick A, Köhne CH, Hiddemann W, Preusser P, Berns T, Seeber S, Wilke H, Schmoll HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N- (phosphonacety)-l-aspartete (PALA) in inactive advanced pancreatic carcinoma. ANN ONCOL, 8: IF: 2, Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C: (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumors. EUR J CANCER, 33: IF: 2, Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C: (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. ANN ONCOL, 8: IF: 2, Hartmannn JT, Schmoll HJ, Thiel I, Kanz L, Bokemeyer C: (1997) Klinische Verlaufsbeobachtung von Patienten mit malignem fibrösen Histiozytom des Knochens und Übersicht zur chemotherapeutischen Behandlung. TUMORDIAGN THER, 1: Jan 34, Hartmann, Schmoll E, Bokemeyer C, Fety, Lucas, D Agay, Schmoll HJ: (1997) Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver

17 metastases from colorectal carcinoma. ONCOL REP, 4: , Köhne C, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N- (phosphonacety)-l-aspartete in Patients with Advanced Colorectal Cancer. Results of a Phase II Study. EUR J CANCER, 33: IF: 2, Köhne C, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J, Rauschecker H, Hill H, Käufer C, Fischer JT, Ohl U, Urbanitz D, Balleisen L, Schmoll HJ: (1997) Phase II Evaluation of 5-Flourouracil plus Folinic acid and alpha 2b-interferon in metastatic colorectal cancer. ONCOLOGY-BASEL, 54: IF: 2, Malek NP, Casper J, Looijenga LH, Strohmeyer T, Schmoll HJ, Nordheim A, Janknecht R: (1997) Quantification of additional short arms of chromosome 12 in germ cell tumors using the polymerase chain reaction. EUR J CANCER, 33: IF: 2, Schmoll HJ: (1997) Prognostic factors for advanced seminoma - a solid basis for clinical trials (Editorial). EUR J CANCER, 9: IF: 2, Schmoll HJ, Bamberg M, Weißbach L: (1997) Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. ONKOLOGIE, 20: , Schmoll HJ, Büchele T, Schöber C: (1997) The role of second line chemotherapy in colorectal cancer. ONKOLOGIE, 20: , Schöber C, Galanski M, Jörgensen M, Schmoll HJ: (1997) Management of endocrine pancreatic tumors. WIEN KLIN WOCHENSCHR, 147: 18-23, Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ: (1997) Analysis of the MHC-Class I antigen presentation machinery in a human embryonal carcinoma cell line: evidence for suppression of TAP, LMP and MHC class I expression. SCAND J IMMUNOL, 46: IF: 1, Weißbach L, Bamberg M, Schmoll HJ: (1997) Interdisciplinary consensus conference on diagnosis and therapy of testicular cancer. UROLOGE, 36: , Summe Bewertung = 11,23117 Summe IF = 34,933

18 1. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1998) Salvagetherapie rezidivierter und refraktärer Hodentumoren. ONKOLOGE, 4: Beyer J, Schmoll HJ: (1998) Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. ONKOLOGE, 4: Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L: (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. BRIT J CANCER, 77: IF: 3, Bokemeyer C, Gerl A, Harstrick A, Schmoll HJ: (1998) Therapie des fortgeschrittenen nichtseminomatösen Keimzelltumors. ONKOLOGE, 4: Bokemeyer T, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A, Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ: (1998) The use of dose-intensified chemotherapy in the treatment of metastatic non-seminomatous testicular germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 25: IF: 2, Dunn T, Schmoll HJ, Rie C, Hartmann K, Casper J: (1998) Production and pre-clinical significance of hematopoietic peptide growth factor (HPGF) in human nonseminomatous germ cell tumor (NSGCT) cell lines. J CANCER RES CLIN, 124: IF: 1, Hartmann JT, Köhne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C: (1998) Is continuous 24-hour infusion of 5-Flourouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II Study. ONCOLOGY-BASEL, 55: IF: 2, Hartmann JT, Schmoll E, Bokemeyer C, Fety R, Lucas C, Giroux B, Schmoll HJ: (1998) Phase I Pharmacological Study of Intra-arterially Infused Fotemustine for Colorectal Liver Metastases. EUR J CANCER, 34: IF: 2, Köhne CH, Schöffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstrick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ: (1998) Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J CLIN ONCOL, 16: IF: 8,228

19 10. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C: (1998) Secondary leukemia following high cumulative doses for Etoposide in Patients treated for advanced germ cell tumors. J CLIN ONCOL, 16: IF: 8, Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Saß G, Seeber S, Thiel E, Berdel WE: (1998) Phase I Clinical and Pharmacokinetic Study of Titanocene Dichloride in adults with advanced solid tumors. CLIN CANCER RES, 4: IF: 2, Schmoll HJ: (1998) Is there a standard adjuvant treatment for colon cancer? (Editorial). EUR J CANCER, 34: IF: 2, Schmoll HJ: (1998) Is there a standard adjuvant treatment for rectal cancer? (Editorial). EUR J CANCER, 34: IF: 2, Schmoll HJ, Beyer J: (1998) Prognostic factors in metastatic germ cell tumors. SEMIN ONCOL, 25: IF: 2, Schmoll HJ, Weißbach L, Bamberg M: (1998) Editorial: Therapie des Hodentumors: das Zauberwort heißt Interdisziplinarität. ONKOLOGE, 4: Summe Bewertung = 11,94738 Summe IF = 39, Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ: (1999) Gemcitabine in patients with relapsed or Cisplatin-refractory testicular cancer. J CLIN ONCOL, 17: IF: 7, Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L: (1999) Treatment of patients with Cisplatinrefractory testicular germ-cell cancer. INT J CANCER, 83: IF: 3, Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C: (1999) First-Line High-Dose Chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J CLIN ONCOL, 17: IF: 7,963

20 4. Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll HJ: (1999) Diagnostisches und therapeutisches Management der oberen Einflussstauung. MED KLIN-INTENSIVMED, 94: Dempke W, Büchele T, Wolf HH, Grothey A, Schmoll HJ: (1999) Diagnostik und Therapie maligner Pleura- und Perikardergüsse. ONKOLOGIE, 22: , Dempke W, Voigt W, Grothey A, Schmoll HJ: (1999) Preferential repair of the N-ras gene in K562 cells after exposure to cisplatin. ANTI-CANCER DRUG, 10: IF: 1, Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mrad GM, Germa-Luch JR, Pont J, Schmoll HJ, Tjulandin S: (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. CANCER-AM CANCER SOC, 85: IF: 3, Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ: (1999) The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J CANCER RES CLIN, 125: IF: 1, Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C: (1999) Long-term effects on sexual function and fertility after treatment of testicular cancer. BRIT J CANCER, 80: IF: 3, Kellner O, Dempke W, Schmoll HJ: (1999) Glukose-Infusionen - eine mögliche effektive Therapieoption bei der Ifosfamid-induzierten Enzephalopathie. DEUT MED WOCHENSCHR, 124: , Schmoll HJ: (1999) Standards in der Behandlung kolorektaler Karzinome - Wunsch und Wirklichkeit. ONCOLOGY-BASEL, 99: 6-7 IF: 2, Schmoll HJ: (1999) Treatment of testicular tumours based on risk factors. CURR OPIN UROL, 9: Schmoll HJ, Büchele T, Grothey A, Dempke W: (1999) Where do we stand with 5-FU? SEMIN ONCOL, 26: IF: 2, Summe Bewertung = 8,43815 Summe IF = 35,767

21 1. Brieger P, Marneros A, Wolf HH, Schmoll HJ: (2000) Manic episode in an ifosfamidetreated patient. GEN HOSP PSYCHIAT, 22: IF: 1, Büchele T, Grothey A, Schmoll HJ: (2000) Neue Perspektiven mit neuen Zytostatika in der Behandlung des kolorektalen Karzinoms. ONKOLOGE, 6: Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ: (2000) Cisplatin resistance and oncogenes - a review. ANTI-CANCER DRUG, 11: IF: 1,57 4. Dempke W, von Poblozki A, Grothey A, Schmoll HJ: (2000) Human hematopoietic growth factors: old lessons and new perspectives. ANTICANCER RES, 20: IF: 1, Grothey A, Kegel T, Dempke W, Schmoll HJ: (2000) Systemische Therapie des hepatozellulären Karzinoms. ONKOLOGE, 6: Kellner O, Voigt W, Schneyer U, Dempke W, Schmoll HJ: (2000) HCG-induced hyperthyreosis in germ cell cancer. ANTICANCER RES, 20: IF: 1, Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schöffski P, Gerigs G, Rüther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C: (2000) First-Line High-Dose chemotherapy + radiation therapy in patients with metastatic germ-cell cancer and brain metastases. ANN ONCOL, 11: IF: 3, Schmiegel W, Adler G, Frühmorgen P, Fölsch U, Greaven U, Layer P, Petrasch S, Porschen R, Pox C, Sauerbruch T, Schmoll HJ, Zeitz M: (2000) Kolorektales Karzinom: Prävention und Früherkennung in der asymptomatischen Bevölkerung - Vorsorge bei Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen. Z GASTROENTEROL, 38: 49-75, Schmoll HJ: (2000) Aktive spezifische Immunotherapie (ASI) beim Kolonkarzinom. STRAHLENTHER ONKOL, 176: IF: 2, Schmoll HJ, Krege S, Souchon R: (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf der Grundlage evidenzbasierter Medizin. ONKOLOGIE, 23: , Schneider I, Rettkowski O, Markau S, Wolf HH, Deuber HJ, Schmoll HJ, Osten B: (2000) Erfassung der Nierenschädigung beim Plasmozytom durch die Cystatin C- Bestimmung im Serum. LABORATORIUMSMEDIZIN, 24: 1900

22 12. Souchon R, Krege S, Schmoll HJ, Albers P, Veyer J, Bokemeyer C, Claßena J, Dieckmann KP, Hartmann M, Heidenreich A, Höltl W, Kliesch S, Köhrmann KU, Kuczyk M, Schmidberger H, Weinknecht S, Winter E, Wittekind C, Bamberg M: (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. STRAHLENTHER ONKOL, 176: IF: 2, Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA: (2000) Final results of a randomized phase II trial of sequential high-dose methotrexate, flourouracil, and doxorubin versus etoposide, leucovorin and flourouracil versus infusion fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J CLIN ONCOL, 18: IF: 8, Voigt W, Bulankin A, Müller T, Schöber C, Grothey A, Hoang-Vu C, Schmoll HJ: (2000) Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. CLIN CANCER RES, 6: IF: 4, von Poblozki A, Dempke W, Schmoll HJ: (2000) Carboxypeptidase-G2-Rescue bei einer Patientin mit Methotrexat-induziertem Nierenversagen. MED KLIN- INTENSIVMED, 95: Summe Bewertung = 6,64826 Summe IF = 29, Bokemeyer C, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Einhorn L, Nichols CR, Hartmann JT: (2001) Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. CANCER-AM CANCER SOC, 91: IF: 3, Dempke W, Rie C, Grothey A, Schmoll HJ: (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J CANCER RES CLIN, 127: IF: 2, Dempke W, Schmoll HJ: (2001) Mögliche neue Indikationen für die Therapie mit Erythropetin. MED KLIN-INTENSIVMED, 96: Dempke W, von Poblozki A, Kellner O, Wolf HH, Schmoll HJ: (2001) Hämorrhagische Diathese als Erstsymptom eines Magenkarzinoms. WIEN KLIN WOCHENSCHR, 112:

23 , Fittkau M, Gerlach R, Schmoll HJ: (2001) Protective effect of oral phosphatidylcholine on radiation-induced release of intestinal peptidases in rats. J CANCER RES CLIN, 127: 444 IF: 2, Fittkau M, Grothey A, Gerlach R, Schmoll HJ: (2001) A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. J CANCER RES CLIN, 127: IF: 2, Fizazi K, Tjulandin S, Salvioni R, Germa-Luch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C: (2001) Viable malignant cells after primary Chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy - results from an international study group. J CLIN ONCOL, 19: IF: 8,53 8. Grothey A, Schmoll HJ: (2001) New Chemotherapy approaches in colorectal cancer. CURR OPIN ONCOL, 13: Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Bokemeyer C: (2001) Second-line chemotherapy in patients with released extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis. J CLIN ONCOL, 19: IF: 8, Hoff PM, Cassidy J, Schmoll HJ: (2001) The evolution of Fluoropyrimidine Therapy: From Intravenous to Oral. ONCOLOGIST, 6: Kellner O, Krüger W, Schmoll HJ: (2001) Standardmanagement von Fieber unklarer Genese (FUO) bei hämatologischen oder onkologischen Patienten in der Neutropenie. PHARMAZIE, 3: 03. Apr, Krege S, Souchon R, Schmoll HJ: (2001) Interdisciplinary consensus on Diagnosis and Treatment of Testicular Germ Cell Tumors: Result of an Update Conference on Evidence-Based Medicine (EBM). EUR UROL, 40: IF: 2, Krege S, Souchon R, Schmoll HJ: (2001) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage evidensbasierter Medizin. UROLOGE, 2:

24 , Rades D, Kühnel G, Wildfang I, Bömer AR, Schmoll HJ, Knapp W, Karstens JH: (2001) Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. ANN ONCOL, 12: IF: 3, Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel W, Kanz L, Siegert W: (2001) Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J CLIN ONCOL, 19: IF: 8, Schmoll HJ: (2001) Kolorektale Karzinome. ONKOLOGIE, 24: 1-8, Schmoll HJ, Cassidy J: (2001) Integrating Oxaliplatin into the Management of Colorectal Cancer. ONCOLOGIST, 6: Wolf HH, Förster W, Schöber C, Grothey A, Dempke W, Schmoll HJ: (2001) Cyclooxigenase-2-inhibitors in colon cancer. ONKOLOGIE,?: #, Summe Bewertung = 5,20094 Summe IF = 44, Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Hartmann JT: (2002) Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J CLIN ONCOL, 20: IF: 9, Fittkau M, Gerlach R, Schmoll HJ: (2002) Phosphatidylcholine does not protect rats against 5-fluorouracil/ folinic acid-induced damage of the intestinal luminal mucosa. J CANCER RES CLIN, 128: IF: 2, Grothey A, Kellermann L, Schmoll HJ: (2002) [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms]. MED KLIN-INTENSIVMED, 97: Krüger WH, Wolf HH, Voigt W, Skibbe T, Schmoll HJ: (2002) Detection of an occult B- cell lymphoma in the donor's bone marrow prior to HLA-matched sibling

25 transplantation. J HEMATOTH STEM CELL, 11: IF: 1, Mantovani L, Hasenclever D, Krahl R, Ponisch W, Herold M, Pasold R, Fiedler F, Dolken G, Kampfe D, Schmoll HJ, Subert R, Kubel M, Niederwieser D, Helbig W: (2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. LEUKEMIA LYMPHOMA, 43: IF: 1, Schmoll HJ: (2002) Extragonadal germ cell tumors. ANN ONCOL, 13: IF: 3, Schmoll HJ: (2002) The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. SEMIN ONCOL, 29(5 Suppl 15): IF: 3,5 8. Schmoll HJ: (2002) Is there a role of high-dose chemotherapy in lymphoma and solid tumours: The present state of the art. CRIT REV ONCOL HEMAT, 41: IF: 2, Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Johnston P, Kerr D, Koehne CH, Labianca R, Minsky B, Nordlinger B, Roth A, Rougier P, Schmoll HJ: (2002) Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). EUR J CANCER, 38: IF: 3, Voigt W, Behrmann C, Schlüter A, Bläser F, Wunderlich D, Harba A, Kegel T, Grothey A, Schmoll E, Schmoll HJ: (2002) Hepatic transcatheter arterial chemoembolisation in refractory liver metastasis of colorectal cancer with Mitomycin C, Interferon- ALPHA2b and Dexamethasone mixed with Amilomer DSM 45/25 (Sperex ) followed by Oxaliplatin, Folinic acid and 5-Fluorouracil - feasibility and preliminary results. ONKOLOGIE, 25: , Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ: (2002) A new chemoembolization protocol in refractory liver metastasis of colorectal cancer--a feasibility study. ONKOLOGIE, 25: , Summe Bewertung = 12,77012 Summe IF = 29, Arnold D, Grothey A, Schmoll HJ: (2003) Neue Entwicklungen in der systemischen Therapie des fortgeschrittenen Kolonkarzinoms. ONKOLOGE, 9: